August 01, 2013

Press Release No. 1

News about Strides Arcolab Limited

The media had reports that Strides Arcolab Limited has received Communication letter regarding concerns of the US FDA for one of its injectable units.

The Exchange, in order to verify the accuracy or otherwise of the information reported in the media and to inform the market place so that the interest of the investors is safeguarded, had written to the company.

Strides Arcolab Limited has vide its letter inter-alia stated, "We confirm that as part of periodic US FDA inspection of one of our units in June 2013, the company received a 483, which an observational document is issued by the US FDA post inspection. The company has responded to the observations within the stipulated period and awaits response from US FDA."

Press Release No. 2

Market-wide Position Limit in FINANTECH

The derivative contracts in the underlying FINANTECH have crossed 95% of the market-wide position limit on August 01, 2013. It is hereby informed that all clients/ members shall trade in derivative contracts of FINANTECH by offsetting their existing positions till the open interest comes down to 80% of the market wide position limit.